February 23, 2017
Oxford Pharmascience’s OXPzero Ibuprofen can act faster in a human study compared to its bioequivalent
Oxford Pharmascience’s interim PK study showed that the technolology modifications can not only make OXPzero Ibuprofen bioequivalent to OTC Nurofen, but also potentially faster acting, the drugmaker said in an update on OXPzero Ibuprofen clinical program, for which on January 17, it kicked off dosing healthy patients in the first phase of the study.